220 related articles for article (PubMed ID: 20107892)
21. Clinical application of gene expression profiling in breast cancer.
Sparano JA; Fazzari M; Kenny PA
Surg Oncol Clin N Am; 2010 Jul; 19(3):581-606. PubMed ID: 20620929
[TBL] [Abstract][Full Text] [Related]
22. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.
Yaal-Hahoshen N; Shina S; Leider-Trejo L; Barnea I; Shabtai EL; Azenshtein E; Greenberg I; Keydar I; Ben-Baruch A
Clin Cancer Res; 2006 Aug; 12(15):4474-80. PubMed ID: 16899591
[TBL] [Abstract][Full Text] [Related]
23. International Agency for Research on Cancer workshop on 'Expression array analyses in breast cancer taxonomy'.
Tavtigian SV; Pierotti MA; Børresen-Dale AL
Breast Cancer Res; 2006; 8(6):303. PubMed ID: 17096863
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling in breast cancer.
Nasser SM
J Med Liban; 2009; 57(2):83-8. PubMed ID: 19623883
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data.
Ruckhäberle E; Karn T; Engels K; Turley H; Hanker L; Müller V; Schmidt M; Ahr A; Gaetje R; Holtrich U; Kaufmann M; Rody A
Eur J Cancer; 2010 Feb; 46(3):549-57. PubMed ID: 20022486
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic molecular classification of breast cancers based on gene expression profiling].
Feng YM; Li XQ; Sun BC; Gao XC; Gu L; Niu Y; Hao XS
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):900-6. PubMed ID: 17533740
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer special types: why bother?
Reis-Filho JS; Lakhani SR
J Pathol; 2008 Dec; 216(4):394-8. PubMed ID: 18798222
[TBL] [Abstract][Full Text] [Related]
28. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer.
Calabrò A; Beissbarth T; Kuner R; Stojanov M; Benner A; Asslaber M; Ploner F; Zatloukal K; Samonigg H; Poustka A; Sültmann H
Breast Cancer Res Treat; 2009 Jul; 116(1):69-77. PubMed ID: 18592372
[TBL] [Abstract][Full Text] [Related]
29. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
[TBL] [Abstract][Full Text] [Related]
30. [Histopathologic diagnosis of luminal and basal type breast cancer].
Sarcević B
Acta Med Croatica; 2008 Oct; 62(4):427-30. PubMed ID: 19205420
[TBL] [Abstract][Full Text] [Related]
31. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients.
Györffy B; Schäfer R
Breast Cancer Res Treat; 2009 Dec; 118(3):433-41. PubMed ID: 19052860
[TBL] [Abstract][Full Text] [Related]
33. Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model.
Rhee DK; Park SH; Jang YK
Genomics; 2008 Dec; 92(6):419-28. PubMed ID: 18804527
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer stratification from analysis of micro-array data of micro-dissected specimens.
Alexe G; Dalgin GS; Scanfeld D; Tamayo P; Mesirov JP; Ganesan S; Delisi C; Bhanot G
Genome Inform; 2007; 18():130-40. PubMed ID: 18546481
[TBL] [Abstract][Full Text] [Related]
35. Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
Reid JF; Lusa L; De Cecco L; Coradini D; Veneroni S; Daidone MG; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2005 Jun; 97(12):927-30. PubMed ID: 15956654
[TBL] [Abstract][Full Text] [Related]
36. Estrogen and progesterone receptor isoforms: clinical significance in breast cancer.
Fuqua SA; Cui Y
Breast Cancer Res Treat; 2004; 87 Suppl 1():S3-10. PubMed ID: 15597215
[TBL] [Abstract][Full Text] [Related]
37. Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel.
Kaufmann M; Pusztai L;
Cancer; 2011 Apr; 117(8):1575-82. PubMed ID: 21472705
[TBL] [Abstract][Full Text] [Related]
38. Biomarker research in breast cancer.
Maxwell C
Clin J Oncol Nurs; 2010 Dec; 14(6):771-83. PubMed ID: 21112854
[TBL] [Abstract][Full Text] [Related]
39. Theranostic and molecular classification of breast cancer.
Cornejo KM; Kandil D; Khan A; Cosar EF
Arch Pathol Lab Med; 2014 Jan; 138(1):44-56. PubMed ID: 24377811
[TBL] [Abstract][Full Text] [Related]
40. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade.
Weigelt B; Baehner FL; Reis-Filho JS
J Pathol; 2010 Jan; 220(2):263-80. PubMed ID: 19927298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
